Hepatitis B

Novel Hepatitis B Virus Treatment Gets FDA's Fast Track Designation

By July 25, 2018

ABI-H0731 is an oral core protein allosteric modifier (CpAM) with selective and potent activity against all major HBV genotypes.

Availability of Generic Antivirals for Hepatitis B Increasing

July 20, 2018

Researchers examined the patent and licensing status of entecavir and tenofovir using the Medicines Patent Pool MedsPaL database.

Long-Term Safety Data for Vemlidy in Chronic Hepatitis B Added to Labeling

By July 05, 2018

Vemlidy, a nucleoside analogue (reverse transcriptase inhibitor), is currently approved to treat chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Hepatitis B Vaccines Compared in Older Adults With Type 2 Diabetes

By June 26, 2018

For the analysis, study authors looked at data specifically for patients with type 2 diabetes aged 60 to 70 years.

HBV Reactivation Examined in Patients Treated With TNF Antagonists

By May 03, 2018

The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.

CDC: Recommendations on the Use of Heplisav-B Published

By April 23, 2018

Benefits of protection with 2 doses administered over 1 month make the vaccine an important option for prevention of HBV.

Raltegravir Labeling Updated With Long-Term Data from Phase 3 HIV Trial

By March 09, 2018

The Isentress (raltegravir) and Isentrress (raltegravir) HD label was recently updated to include Week 96 data from the Phase 3 trial (ONCEMRK).

ACIP Recommends Use of Heplisav-B for Hepatitis B Prevention in Adults

By February 21, 2018

The Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including Heplisav-B on its list of ACIP recommended products.

Heplisav-B Now Available for Hepatitis B Prevention in Adults

By January 08, 2018

Heplisav-B is the first and only two-dose vaccine for prevention of hepatitis B in adults.

Viread Generic Now Available From Teva

By December 19, 2017

Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor.

ACP/CDC: Best Practice Advice for Hepatitis B Vaccination, Screening

November 21, 2017

All unvaccinated adults at risk for infection should be vaccinated; screening recommended for at-risk

New Vaccine for Hepatitis B Gets FDA Approval

By November 10, 2017

Two-dose vaccine for the prevention of hepatitis B in adults.

AAP: Hepatitis B Vaccine Should Be Given Within First 24 Hours of Life

August 29, 2017

Birth vaccine should be given for all medically stable infants weighing 2,000 g

EASL: 2017 HBV Infection Management Guidelines

By April 20, 2017

The updated guidelines include new definitions of disease phases, expanded indications for initiating treatment and recommendations for special populations.

Clinician Fails to Follow Up on Crucial Information

By March 02, 2017

This case examines a situation where a physician did not act on a bit of information that he should have taken quite seriously.

Tocilizumab-Related HBV Reactivation Examined in RA

February 13, 2017

Three patients with chronic HBV infection had reactivation, but they were asymptomatic

FDA Approves New Drug for Chronic HBV Infection

By November 11, 2016

The Food and Drug Administration (FDA) has approved Vemlidy (tenofovir alafenamide [TAF]) for the treatment of adults with hepatitis B virus (HBV) infection with compensated liver disease.